Literature DB >> 15993791

Surgery alone versus surgery and doxorubicin for the treatment of feline injection-site sarcomas: a report on 69 cases.

Marina Martano1, Emanuela Morello, Maura Ughetto, Selina Iussich, Claudio Petterino, Paolo Cascio, Paolo Buracco.   

Abstract

Sixty-nine cats were treated for injection-site sarcomas at the Veterinary Teaching Hospital of Grugliasco, Turin (Italy). The animals were divided into two subgroups: those subjected to four doxorubicin cycles combined with radical surgical excision 10 days after the second chemotherapy cycle (group A, 49 cats) or those treated with surgery alone (group B, 20 cats). Each cat was monitored for lung metastasis and local recurrence. In group A, 28 cats were alive at the end of the follow-up period. In this group, the recurrence rate was 40.8% while lung metastasis occurred in 12% of cats. In group B, eight animals were alive at the end of the follow-up period, while the rates of recurrence and metastasis were 35% and 10%. Neither the median disease-free interval nor the median overall survival was reached in either group. Moreover, there were no statistically significant differences between the two groups.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15993791     DOI: 10.1016/j.tvjl.2004.04.004

Source DB:  PubMed          Journal:  Vet J        ISSN: 1090-0233            Impact factor:   2.688


  9 in total

1.  Photodynamic hyperthermal chemotherapy with indocyanine green in feline vaccine-associated sarcoma.

Authors:  Masaki Onoyama; Takeshi Tsuka; Tomohiro Imagawa; Tomohiro Osaki; Akihiko Sugiyama; Kazuo Azuma; Norihiko Ito; Kazuhiko Kawashima; Yoshiharu Okamoto
Journal:  Oncol Lett       Date:  2015-08-03       Impact factor: 2.967

Review 2.  Current knowledge on feline injection-site sarcoma treatment.

Authors:  Katarzyna Zabielska-Koczywąs; Anna Wojtalewicz; Roman Lechowski
Journal:  Acta Vet Scand       Date:  2017-07-17       Impact factor: 1.695

Review 3.  Vaccine-associated feline sarcoma: current perspectives.

Authors:  Corey F Saba
Journal:  Vet Med (Auckl)       Date:  2017-01-12

4.  Biological indicators of chemoresistance: an ex vivo analysis of γH2AX and p53 expression in feline injection-site sarcomas.

Authors:  Yike Bing; Zacharie Wund; Tina Abratte; Lucia Borlle; Susie Kang; Teresa Southard; Kelly R Hume
Journal:  Cancer Cell Int       Date:  2018-11-22       Impact factor: 5.722

5.  Welfare-Adjusted Life Years (WALY): A novel metric of animal welfare that combines the impacts of impaired welfare and abbreviated lifespan.

Authors:  Kendy Tzu-Yun Teng; Brecht Devleesschauwer; Charline Maertens De Noordhout; Peter Bennett; Paul D McGreevy; Po-Yu Chiu; Jenny-Ann L M L Toribio; Navneet K Dhand
Journal:  PLoS One       Date:  2018-09-12       Impact factor: 3.240

6.  Neoadjuvant and adjuvant doxorubicin chemotherapy in a case of feline soft tissue sarcoma.

Authors:  Filippo Torrigiani; Giorgio Romanelli; Paola Roccabianca; Elisabetta Treggiari
Journal:  JFMS Open Rep       Date:  2019-07-01

7.  Combination of bleomycin and cisplatin as adjuvant electrochemotherapy protocol for the treatment of incompletely excised feline injection-site sarcomas: A retrospective study.

Authors:  Enrico P Spugnini; Bruno Vincenzi; Francesca Carocci; Chiara Bonichi; Francesco Menicagli; Alfonso Baldi
Journal:  Open Vet J       Date:  2020-07-31

8.  Origins of injection-site sarcomas in cats: the possible role of chronic inflammation-a review.

Authors:  Kevin N Woodward
Journal:  ISRN Vet Sci       Date:  2011-04-12

9.  Adjuvant immunotherapy of feline fibrosarcoma with recombinant feline interferon-omega.

Authors:  Verena Hampel; Bianca Schwarz; Christine Kempf; Roberto Köstlin; Ulrike Schillinger; Helmut Küchenhoff; Nora Fenske; Thomas Brill; Johannes Hirschberger
Journal:  J Vet Intern Med       Date:  2007 Nov-Dec       Impact factor: 3.333

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.